- Apnimed eyes up to $160M IPO to prep for sleep apnea drug launchIf the offering closes, Apnimed will join the 2026 IPO class that has already far surpassed last year’s total.
- Oak Hill takes SPAC track to Nasdaq with Roche asset in towOak Hill Bio is developing the antisense therapy rugonersen, which it licensed from Roche in 2025, for Angelman syndrome.